Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: episodic (5), intermittent (36), sporadic (4)

DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards

Description: Chemotherapy Protocol Myeloma DVd (weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 9 onwards) Regimen • Myeloma – Bortezomib (weekly) with daratumumab and dexamethasone Indication • Daratumumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-weekly-Cycles-9-onwards.pdf

Daratumumab

Description: Chemotherapy Protocol Myeloma Daratumumab Regimen • Myeloma – Daratumumab monotherapy Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and refractory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab.pdf

DVd_Twice weekly_Daratumumab-Bortezomib-Dexamethasone_Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (twice weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (twice weekly)-Daratumumab-Dexamethasone Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Twice-weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly)-Daratumumab-Dexamethasone Indication • Daratumumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

Pazopanib v1.1

Description: Chemotherapy Protocol RENAL CELL PAZOPANIB Regimen Renal Cell - Pazopanib Indication First line treatment option for people with advanced renal cell carcinoma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Pazopanib-v1.1.pdf

Carboplatin AUC2-RT

Description: Chemotherapy Protocol HEAD AND NECK CANCER CARBOPLATIN (AUC2)-RADIOTHERAPY Regimen • Head and Neck Cancer – Carboplatin(AUC2)-Radiotherapy Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Carboplatin-AUC2RT.pdf

Carboplatin AUC1.5+RT

Description: Chemotherapy Protocol HEAD AND NECK CANCER CARBOPLATIN (AUC1.5)-RADIOTHERAPY Regimen • Head and Neck Cancer – Carboplatin(AUC1.5)-Radiotherapy Indica
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Carboplatin-AUC1.5RT.pdf

NilotinibChronic

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Nilotinib (chronic phase) Regimen • CML – Nilotinib (chronic phase) Indication • As an option for the treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/NilotinibChronic.pdf

NilotinibAccelerated

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Nilotinib (accelerated phase) Regimen • CML – Nilotinib (accelerated phase) Indication • Nilotinib is an option for the treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/NilotinibAccelerated.pdf

Niraparib

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCERS Regimen NIRAPARIB • Ovarian Cancer – Niraparib Indication • Niraparib is recommended as maintenance treatment in patients with relapsed, platinum
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Niraparib.pdf

71 to 80 of 187

Previous … 6 7 8 9 10 … Next